<DOC>
	<DOCNO>NCT00505635</DOCNO>
	<brief_summary>The goal clinical research study learn treatment Temodar ( temozolomide ) , Velban ( vinblastine ) , Cisplatin , Proleukin ( interleukin-2 ) , Intron-A ( interferon alpha ) , thalidomide help control melanoma spread part body . The safety treatment also study .</brief_summary>
	<brief_title>Biochemotherapy With Temozolomide Metastatic Melanoma</brief_title>
	<detailed_description>Some drug study use DTIC ( Dacarbazine ) past control Melanoma spread part body . However , case , duration result limit ineffective control prevent spread disease brain , membrane cover brain , spinal cord , nerve root . In study , temozolomide use instead DTIC . Temodar proven one effective therapeutic agent control malignancies brain . Thalidomide design decrease formation new blood vessel fee tumor . The treatment plan study divide two part . The first part study ( induction therapy ) do try get disease control . The second part study ( maintenance therapy ) maintain improve result first part treatment plan . Induction Therapy : Induction therapy include three 5-day course treatment thalidomide , temozolomide , vinblastine , cisplatin , interleukin-2 , interferon-alpha . The course repeat cycle three four week depend recovery side effect previous course treatment . All drug give vein give catheter ( plastic tube ) insert vein one arm vein run underneath collar bone thread central vein upper part chest . You admitted hospital Day 0 . You start receive liquid ( hydration ) prepare start temozolomide day 1 admission . It anticipate remain hospital one week . Depending degree side effect longer stay hospital may require . Temozolomide give mouth first day treatment every 4 hour three dos . A fourth dose may consider late course treatment well tolerate . Vinblastine give catheter Days 1,2,3 4 cycle . The infusion last 15 30 minute . Cisplatin give catheter Days 1,2,3 4 cycle . The infusion last 45 120 minute . Care give fully hydrate body decrease chance kidney damage . Thalidomide give mouth day throughout cycle treatment . It give single dose start Day 0 , day start temozolomide , every day entire cycle . Interleukin-2 give continuous infusion catheter 24 hour four day row ( 96 hour ) . It give Day 1 Day 5 cycle . Interferon alpha give `` insulin-type injection '' skin , fatty tissue , day Days 1,2,3,4 5 cycle You receive 3 course induction therapy . The course repeat cycle 3-4 week depend adequate recovery side effect . If stable disease improve disease , go receive maintenance therapy . Maintenance Therapy : Long-term daily treatment study drug give six 4-week cycle . Temozolomide give mouth daily 21 day ( 3 week ) . This follow one week without Temozolomide treatment . This make one cycle treatment . Interleukin-2 interferon alpha give one week rest temozolomide . This require one week hospitalization . Interleukin-2 give continuous infusion catheter first 5 day . The first day dose high decrease slowly low dose last 3 day . The interferon alpha give injection fatty tissue skin day 5 day day interleukin-2 give . Thalidomide give mouth day every day full 4-week cycle . Supportive care medication fever , chill , nausea , vomit , diarrhea , give treatment . You also give fluid appropriate electrolyte replenish blood level replenish blood volume help kidneys . How respond treatment evaluate computed tomography ( CT ) scan magnetic resonance image ( MRIs ) brain . This occur second course third course induction therapy third sixth course maintenance therapy periodically study . You request complete questionnaire evaluate quality life treatment start , end Cycles 2 3 induction therapy , end Cycles 3 6 maintenance therapy . You take study disease get bad intolerable side effect occur . Should take study early , long term follow-up request . For patient complete treatment , radiographic evaluation body CT scan brain MRI do . They physical exam , blood test ( 1 2 tablespoon per visit ) every 3 month first year , every 4 month second year , every 6 month 5th year , year . A total 60 patient take part study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Patients histologically document diagnosis advanced stage IV unresectable stage III melanoma eligible . 2 . They recurrent melanoma measureable evaluable site disease order ass response treatment Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion . 3 . Patients 18 year age 65 year age expect survival great 8 week Karnofsky performance status 50 % good Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 eligible . 4 . They normal blood count white blood count ( WBC ) count equal 3000/mm^3 absolute neutrophil count equal 1500/mm^3 platelet count 100,000/mm^3 impairment renal function ( serum creatinine le 1.6 mg/dl ) , hepatic function ( serum bilirubin level &lt; 1.2 mg/dl ) evidence significant cardiac pulmonary dysfunction . 5 . They significant intercurrent illness active infection , uncontrolled psychiatric illness , hypercalcemia ( calcium &gt; 11 mg ) , active GI bleeding . 6 . They expose previous chemotherapy isolation perfusion malignant melanoma previous exposure interleukin2 . Prior adjuvant interferon permit . Prior radiation therapy metastatic melanoma permit provided patient unirradiated metastatic site response evaluation fully recover toxicity . 1 . Patients brain and/or bone metastasis . 2 . Patients symptomatic central nervous system involvement melanoma either brain metastasis MRI spinal cord compression . Patients brain metastasis eligible unless disease resect , asymptomatic , associated cerebral edema , clinically stable radiation corticosteroid therapy 4 week . No major surgery RT within 21 day start treatment . 3 . Patients significant cardiac illness symptomatic coronary artery disease previous history myocardial infarction , impaired leave ventricle function ( EF &lt; 55 % ) account organic disease hypertension valvular heart disease serious cardiac arrhythmia require therapy . Patients electrocardiogram ( EKG ) disclose absolute QT interval &gt; 460 msec presence serum potassium &gt; /=4.0 mEq/L magnesium &gt; /= 1.8 mg/dL . Patients heart rate le 50 . 4 . Patients significant impairment pulmonary function account chronic bronchitis chronic obstructive pulmonary disease ( COPD ) result impairment vital capacity Left Ventricular Ejection Fraction ( FE VI ) &lt; 75 % predict normal value . 5 . Patients symptomatic effusion account pleural , pericardial peritoneal metastasis melanoma . 6 . Patients unable stay Houston receive therapy ( first cycle ) able return followup visit require study . 7 . Patients history second malignant tumor , common skin cancer basal squamous carcinoma , within past 5 year uncertainty histological nature metastatic lesion . 8 . Patients history deep vein thrombus ( DVT ) pulmonary embolism ( PE ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>advanced stage IV melanoma</keyword>
	<keyword>unresectable stage III melanoma</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Velban</keyword>
	<keyword>Vinblastine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Intron-A</keyword>
	<keyword>Interferon Alpha-2b</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Thalomid</keyword>
	<keyword>Temodar</keyword>
	<keyword>Proleukin</keyword>
</DOC>